Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

rter of 2010. U.S. sales of Byetta decreased 3 percent to $128.1 million compared with the third quarter of 2010 due to competitive pressures, while sales of Byetta and Bydureon outside the U.S. increased 18 percent to $42.9 million.

Effient®

Effient sales were $83.5 million in the third quarter of 2011, up from $71.7 million in the second quarter of 2011 due to increased demand. U.S. Effient sales were $61.4 million. Sales outside the U.S. were $22.1 million.

Animal Health

Worldwide sales of animal health products in the third quarter of 2011 were $451.0 million, an increase of 28 percent compared with the third quarter of 2010. U.S. sales grew 20 percent, to $237.9 million, due to increased demand for food animal products and the recent U.S. launch of Trifexis™. Sales outside the U.S. increased 37 percent, to $213.2 million, driven by the impact of the acquisition of certain Janssen and Pfizer animal health assets in Europe, and to a lesser extent the favorable impact of foreign exchange rates and increased demand.

2011 Financial Guidance The company has updated certain elements of its 2011 financial guidance. The company has narrowed its full-year 2011 non-GAAP earnings per share guidance to a range of $4.30 to $4.35 per share. On a reported basis, the company now expects full-year 2011 earnings per share to be in the range of $3.89 to $3.94. Earnings per share guidance excludes potential future restructuring charges.

2011 Earnings Per Share Expectations:2011
Expectations2010
Results% GrowthEarnings per share (reported)$3.89 to $3.94$4.58(14)% to (15)%In-process research and development charges
  associated with Boehringer Ingelheim
  collaboration (2011) and Acrux licensing
  agreement (2010)

.23.03Asset impairments and restructuring charges

.18.13Earnings per share (non-GAAP)$4.30 to $4.35$4.74(8)% to (9)%The company still expects total revenue to grow in th
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Declares Fourth-Quarter 2011 Dividend
2. Lilly Announces Changes in Senior Management
3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
7. Lilly Health Channel Debuts on YouTube
8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... April 13, 2011 Cephalon, Inc. (Nasdaq: ... CXS Holdings Pty Ltd (Cephalon), has lodged the offer ... for ChemGenex Pharmaceuticals Limited (ASX: CXS) (ChemGenex) with the ... offering a 58 percent premium to the one-month volume ...
... Pharmaceuticals, Inc., the leader in the development of neurosteroids ... of a $3 million grant by the U.S. Department ... the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ... Early research suggests that normalizing neurosteroid levels with ganaxolone ...
Cached Medicine Technology:Cephalon Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals 2Cephalon Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals 3Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome 2
(Date:4/23/2014)... State University Spokane have developed a new way ... off behind the wheel. , Their recently patented ... more variable in drowsy driversand offers an affordable ... driver drowsiness detection systems. , Van Dongen"Video-based systems ... is drifting out of its lane are cumbersome ...
(Date:4/23/2014)... University researcher is looking to give exercise enthusiasts the ... latest research shows that a cyber buddy can help. ... for Health Journal , is the first to indicate ... motivator during exercise, a software-generated partner also can be ... isn,t real can still motivate people to give greater ...
(Date:4/23/2014)... rats exposed to high-energy particles, simulating conditions astronauts would ... in attention and slower reaction times, even when the ... The cognitive impairments which affected a large subset, ... to be linked to protein changes in the brain, ... true in humans, suggest it may be possible to ...
(Date:4/23/2014)... researchers have identified an important enzyme pathway that helps ... few chromosomes, a condition that has been directly linked ... professor of biochemistry, found that near the end of ... that ensures any breaks in DNA are fully repaired ... to daughter cells. This process helps safeguard against some ...
(Date:4/23/2014)... has long been considered to be between 180 and ... used refined microscopic techniques that indicate a much smaller ... tract is only as large as a normal studio ... which passes from the mouth through the esophagus and ... 5 meters in a normal adult, and is built ...
Breaking Medicine News(10 mins):Health News:WSU innovation improves drowsy driver detection 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... THE MARKET FORECAST FOR THE DRUG, WALTHAM, Mass., ... Resources, is available to discuss the impact of the ... the,first integrase inhibitor drug which blocks the ability of ... Integrase inhibitors are a novel class of HIV drugs ...
... New products, a growing world,population expected to ... as the,aging of that population, will push anesthesia ... according to Anesthesia Drugs: Worldwide Markets, a,new report ... surgical procedures required anesthetic,administration worldwide in 2006, and ...
... SYK ) disclosed today that the United ... inquiry of the Company regarding possible,violations of the ... sale,of medical devices in certain foreign countries. Stryker ... Commission regarding this,informal investigation. Stryker Corporation is ...
... 118 patients with portal vein thrombosis, noncirrhotic and nontumoral ... well tolerated bleed. Cirrhosis and tumor related portal vein ... state as a cause of portal vein thrombosis is ... number of patients. , A research article to be ...
... health information program recognized for helping to reduce, ... self-care., INDIANAPOLIS, Oct. 12 WellPoint NextRx, ... has received a 2007,Disease Management Leadership Award from ... innovative, Web-based Health Envelope(R) Program.,WellPoint NextRx is owned ...
... /Xinhua-PRNewswire-FirstCall/ -- China,Medicine Corporation ("CMC") (OTC ... prescription and over the counter pharmaceutical ... of Chinese herbs),Chinese herbs, nutritional supplements, ... today announced the Company,s ADTZ,(Aflatoxin-detoxifizyme) project ...
Cached Medicine News:Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2Health News:Anesthesia Drugs Market to Grow to $4.3 Billion by 2011 as Populations and Uses for Anesthesia Increase 2Health News:Portal vein thrombosis is common in extraportal vein obstruction 2Health News:WellPoint NextRx Receives National Leadership Award for Innovative Web Tool 2Health News:WellPoint NextRx Receives National Leadership Award for Innovative Web Tool 3Health News:China Medicine's ADTZ Project Has Been Selected as One of Six Patent Commercialization Projects in Guangdong Province 2
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Gradua...
Laser resistant tubes for use with CO2 and KTP Lasers., ,Designed for airway management during laser surgery of the larynx or other areas in close proximity to the trachea....
Laryngectomy Tubes with special J-shape for convenient placement through a tracheostomy stoma....
SPIRAL-FLEX® Reinforced Oral/Nasal Cuffed Endotracheal Tubes...
Medicine Products: